"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves gilteritinib (XOSPata) for treatment of adult patients who have relapsed or refractory AML

14 Jan 2019 3:27 PM | Anonymous

The U.S. Food and Drug Administration approved gilteritinib (Xospata; Astellas) for treatment of adult patients who have relapsed or refractory acut myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA approved test. Read full press release.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software